ARIX.L Regulatory News (ARIX)

ARIX.L Information

There is currently no data for ARIX

REMOVE ADS

Director Declaration

17 Oct 2017 07:10

RNS Number : 7531T

BTG PLC

17 October 2017

BTG plc

17 October 2017

Director Declaration

BTG plc announces today that Mr Giles Kerr, Non-executive Director of the Company, has been appointed as a Non-executive Director and Audit Committee Chair of Arix Bioscience plc with effect from 17 October 2017.

This announcement is made pursuant to Listing Rule 9.6.14(2).

Contacts:

Andy Burrows, Vice President, Corporate and Investor Relations

+44 (0)20 7575 1741

This information is provided by RNS

The company news service from the London Stock Exchange

END

RDNMMMMGMVVGNZZ

Date		Source	Headline
16th Mar 2023	7:01 am	EQS	Unaudited NAV for February 2023
14th Feb 2023	6:19 pm	EQS	Portfolio company Disc Medicine announces $62.5 million financing
6th Feb 2023	6:00 pm	EQS	Director/PDMR Shareholding
6th Feb 2023	5:00 pm	EQS	Director/PDMR Shareholding
6th Feb 2023	8:00 am	EQS	Unaudited NAV for January 2023
6th Feb 2023	7:00 am	EQS	Unaudited NAV for January 2023
30th Jan 2023	8:00 am	EQS	Unaudited NAV for December 2022
30th Jan 2023	7:00 am	EQS	Unaudited NAV for December 2022
26th Jan 2023	8:00 am	EQS	Board Change
26th Jan 2023	7:00 am	EQS	Board Change
5th Jan 2023	5:20 pm	EQS	Portfolio company Twelve Bio to be acquired alongside $85 million financing of Ensoma
5th Jan 2023	4:21 pm	EQS	Portfolio company Twelve Bio to be acquired alongside $85 million financing of Ensoma
30th Dec 2022	8:01 am	EQS	Portfolio Company Disc Medicine Completes Merger with Gemini Therapeutics
30th Dec 2022	7:01 am	EQS	Portfolio Company Disc Medicine Completes Merger with Gemini Therapeutics
12th Dec 2022	8:00 am	EQS	Unaudited NAV for November 2022
12th Dec 2022	7:01 am	EQS	Unaudited NAV for November 2022
6th Dec 2022	8:00 am	EQS	Arix to Present at Mello Investment Trusts & Funds
6th Dec 2022	7:00 am	EQS	Arix to Present at Mello Investment Trusts & Funds
1st Dec 2022	7:45 am	RNS	Director/PDMR Shareholding
9th Nov 2022	8:00 am	EQS	Unaudited NAV for October 2022
9th Nov 2022	7:00 am	EQS	Unaudited NAV for October 2022
28th Oct 2022	7:00 am	EQS	Director/PDMR Shareholding
28th Oct 2022	7:00 am	EQS	Director/PDMR Shareholding
20th Oct 2022	4:30 pm	EQS	Holding(s) in Company
20th Oct 2022	4:30 pm	EQS	Holding(s) in Company
14th Oct 2022	7:00 am	EQS	Portfolio Company Imara Announces Merger Agreement with Enliven Therapeutics
14th Oct 2022	7:00 am	EQS	Portfolio Company Imara Announces Merger Agreement with Enliven Therapeutics
11th Oct 2022	7:00 am	EQS	Unaudited NAV for September 2022
11th Oct 2022	7:00 am	EQS	Unaudited NAV for September 2022
5th Oct 2022	7:00 am	EQS	Director/PDMR Shareholding
5th Oct 2022	7:00 am	EQS	Director/PDMR Shareholding
3rd Oct 2022	4:32 pm	EQS	Arix Portfolio Company Aura Biosciences Presents Interim Phase 2 Data Highlighting Belzupacap Sarotalocan (AU-011) Suprachoroidal Efficacy and Safety at AAO 2022
3rd Oct 2022	4:31 pm	EQS	Arix Portfolio Company Aura Biosciences Presents Interim Phase 2 Data Highlighting Belzupacap Sarotalocan (AU-011) Suprachoroidal Efficacy and Safety at AAO 2022
15th Sep 2022	7:01 am	EQS	Unaudited NAV for August 2022
15th Sep 2022	7:00 am	EQS	Unaudited NAV for August 2022
12th Aug 2022	7:00 am	EQS	Unaudited NAV for July 2022
12th Aug 2022	7:00 am	EQS	Unaudited NAV for July 2022
10th Aug 2022	6:05 pm	EQS	Artios initiates Phase 2 study of Polθ Inhibitor ART4215 in Combination with PARP Inhibitor Talazoparib in BRCA Deficient Breast Cancer
10th Aug 2022	6:05 pm	EQS	Artios initiates Phase 2 study of Polθ Inhibitor ART4215 in Combination with PARP Inhibitor Talazoparib in BRCA Deficient Breast Cancer
10th Aug 2022	5:46 pm	EQS	Portfolio Company Disc Medicine Enters Definitive Merger Agreement with Gemini Therapeutics
10th Aug 2022	5:46 pm	EQS	Portfolio Company Disc Medicine Enters Definitive Merger Agreement with Gemini Therapeutics
10th Aug 2022	7:01 am	EQS	Interim Results for the Six Months Ended 30 June 2022
10th Aug 2022	7:01 am	EQS	Arix Bioscience plc Announces Changes to Board of Directors
10th Aug 2022	7:01 am	EQS	Arix Bioscience plc Announces Changes to Board of Directors
10th Aug 2022	7:00 am	EQS	Interim Results for the Six Months Ended 30 June 2022
3rd Aug 2022	7:00 am	EQS	Notice of Results & Investor Presentation
3rd Aug 2022	7:00 am	EQS	Notice of Results & Investor Presentation
22nd Jul 2022	7:00 am	EQS	Unaudited NAV for June 2022
22nd Jul 2022	7:00 am	EQS	Unaudited NAV for June 2022
22nd Jun 2022	4:45 pm	EQS	Holding(s) in Company

Latest Share Chat

ARIX.L Regulatory News (ARIX)

Director Declaration

Please enter at least 2 characters

No results found

Search results

Recently viewed

Trending